Correction: From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis
Elisabeth Schnoy, Axel Dignass, Matthew Gaskins, Torsten Kucharzik
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsInflammatory Bowel Disease · Clostridium difficile and Clostridium perfringens research · Microscopic Colitis
In the above-mentioned article in Table 1 a bullet point in the rectum column for Salofalk Granu-Stix was included and “pH-dependent plus additional enzymatic activation (non-pH-dependent)” in the pH release profile column for Asacol 1600 mg modified-release tablets was added ( Table 1 ).
Additionally in reference number 79 the link to the "Fachinformation (SmPC) Claversal 500 mg magensaftresistente Tabletten” was changed. The correct link in this case is as follows:
https://www.fachinfo.de/fi/detail/021892/claversal-r-500-mg-tabletten?query=claversal%20500 .
This was corrected in the online version on March 13th, 2026.